Point of Care Instrument - Atlas io™ Reader Enters Clinical Study Stage
Atlas Genetics Ltd have finished development of the Atlas io™ Reader, a POC device that can deliver laboratory quality results for molecular assays in under thirty minutes.
The Atlas io™ Reader, developed with The Technology Partnership plc operates with a disposable cartridge, to which an unprocessed clinical specimen is added. The instrument fully automates the three-stage process of sample preparation, DNA amplification, and electrochemical detection to analyse the patient’s sample for the target infection.
The Atlas io™ Reader is now entering pilot manufacture ahead of the company conducting clinical studies to support its application for regulatory clearance in Europe later this year.
Tags: Carbapenemase Resistant Enterobacteriaceae (CRE), Clostridium difficile, Methicillin Resistant S. Aureus, Vancomycin Resistant Enterococcus, MRSA, New Delhi Metallo-beta-lactamase NDM-1, Chlamydia, Neisseria, Sepsis
Date Published: January 24, 2014 » company contact details
LiDia® BSI Test: Detection of Pathogens in Clinical Whole Blood Samples
Study Outlines ‘Perfect Storm’ that Led to Antibiotic Resistance Epidemic
New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Clindamycin (CD)